Under the terms of the agreement, Centocor will have rights to utilize the deltaPhase technology in their research. PhaseBio’s deltaPhase technology is said to offer new solutions for the production and purification of protein-based therapeutics, including polypeptides, proteins or antibodies and provides substantial advantages over current biological production methods.
Clay Thorp, chairman of the board, Phase Bioscience, said: “We are extremely pleased that Centocor has decided to extend their successful collaboration with PhaseBio.”